Tocris to supply gefitinib to cancer researchers
This article was originally published in Scrip
Tocris Bioscience, a UK-based pharmaceutical supplier, has signed an exclusive deal with AstraZenecato supply the lung cancer drug gefitinib (also marketed as Iressa and Geffy) to preclinical researchers exploring cancer mechanisms. This will enable scientists to buy the fully licensed, non-formulated drug as an off-the-shelf product for use in biological research. Gefitinib has been licensed to Tocris for use as a preclinical research compound only and AstraZeneca has imposed conditions to ensure that it is not used in human studies. Last month gefitinib showed a benefit in progression-free survival over carboplatin plus paclitaxel in the first line treatment of selected non-small cell lung cancer patients (ScripOnline, August 8th, 2008).
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.